The development of resistance to chemotherapeutic drugs is a major obstacle to the successful treatment of breast cancer. Ways to block or overcome this resistance are objects of intense research. We have previously shown that cancer cells selected for resistance against chemotherapeutic drugs or isolated from metastatic tumor sites have high levels of a calcium-dependent protein crosslinking enzyme, tissue transglutaminase (TG2) but no direct link between TG2 and resistance was established. As TG2 can associate with the b members of the integrin family of proteins, we hypothesized that TG2 promotes cell survival signaling pathways by activating integrins on the surface of these cells. To test this hypothesis, we studied the expression of TG2 and its interaction with various integrins in drug-resistant MCF-7 breast cancer cells. TG2 closely associated with b1 and b5 integrins on the surface of drug-resistant MCF-7 (MCF-7/Dox and MCF-7/RT) cells. The incubation of TG2-expressing drug-resistant MCF-7 cells on fibronectin (Fn)-coated surfaces strongly activated focal adhesion kinase, an event that leads to the activation of several downstream signaling pathways and, in turn, can confer apoptosisresistant phenotype to cancer cells. The role of TG2 in Fnmediated cell attachment, cell growth, and cell survival functions was further analysed by small interfering RNA (siRNA) approach. Inhibition of TG2 by siRNA-inhibited Fn-mediated cell attachment and cell survival functions in drug-resistant MCF-7 cells. We conclude that the expression of TG2 in breast cancer cells contributes to the development of the drug-resistance phenotype by promoting interaction between integrins and Fn.
Introduction
The two factors responsible for most breast cancerrelated deaths are the ability of cancer cells to metastasize and their capacity to express resistance to anti-cancer therapies. Indeed, resistance to chemotherapy is a major obstacle to successful treatment of breast cancer. Ways to block or overcome this resistance are objects to intense research.
Our laboratory has been working on understanding the biochemical pathways that underlie the development of the drug-resistance phenotype. Previously, we have established a direct relationship between the development of drug resistance and metastatic phenotypes in breast cancer and increased expression of a protein crosslinking enzyme, tissue transglutaminase (TG2) (Mehta, 1994; Chen et al., 2002; Mehta et al., 2004 ). An important member of the transglutaminase family of enzymes, TG2 catalyses the Ca 2 þ -dependent posttranslational modification of proteins by inserting highly stable isopeptide bonds and/or inducing covalent incorporation of polyamines and histamines into proteins (Chen and Mehta, 1999; Lorand and Graham, 2003) . Many reports have supported the involvement of TG2 in apoptosis; its overexpression-primed cells for apoptosis whereas its inhibition by antisense RNA rendered the cells resistant to apoptosis induction (Fesus et al., 1991; Davies and Piacentini, 1994; Oliverio et al., 1997; Autuori et al., 1998) . Contrary to this, recent evidence indicates that increased expression of TG2 may prolong cell survival by preventing apoptosis (Antonyak et al., 2001; 2004; Boehm et al., 2002; Mangala and Mehta, 2005) . For example, by catalysing transamidation of retinoblastoma protein (pRB) TG2 could confer protection against N-(4-hydroxyphenyl)retinamide-induced apoptosis in HL-60 cells (Antonyak et al., 2001; Boehm et al., 2002) . Similarly, epidermal growth factor that promotes the expression of TG2 has been shown to protect breast cancer cells from doxorubicin-induced apoptosis (Antonyak et al., 2004) . Moreover, TG2 (À/À) knockout mice did not display any phenotype that could be ascribed to perturbed apoptosis (De Laurenzi and Melino, 2001; Nanda et al., 2001) . As the causes of these discrepancies are unrevealed what is becoming apparent is that whether proapoptotic or antiapoptotic functions of TG2 are activated may depend on TG2's location within the cell (Milakovic et al., 2004) . For example, extremely stressful conditions (hypoxia, growth factor deprivation, or treatment with chemotherapeutic drugs) that lead to sudden perturbations in Ca 2 þ homeostasis can convert cytosolic TG2 into its crosslinking configuration, resulting in extensive polymerization of intracellular proteins and formation of detergent-insoluble crosslinked protein scaffold. The insoluble protein scaffold thus formed can stabilize the integrity of the dying cell before its clearance by phagocytosis, preventing the release of harmful intracellular components and consequent inflammatory responses (Fesus et al., 1991) . In the nucleus, TG2 can interact with and result in the polyamination of the pRB that protect cells from apoptotic insults (De Laurenzi and Melino, 2001; Nanda et al., 2001; Boehm et al., 2002; Antonyak et al., 2004; Milakovic et al., 2004; Mangala and Mehta, 2005) . Similarly, in the cell membrane, TG2 can associate with integrins (Akimov et al., 2000; Akimov and Belkin, 2001 ) and provide a binding site for fibronectin (Fn) (Jeong et al., 1995) . TG2 exerts this function by simultaneously binding to b integrins and Fn through a gelatin-binding domain (42-kDa fragment, modules I 6 II 1,2 I 7-9 ) (Akimov et al., 2000) .
Based on these observations and our previous findings that drug resistant and metastatic breast cancer cells express high levels of TG2 (Mehta, 1994; Chen et al., 2002; Mehta et al., 2004) , we hypothesized that TG2 expression confers apoptosis resistance to breast cancer cells and protects them from drug-induced apoptosis by promoting integrin-mediated interaction of cells with Fn and activating cell survival signaling pathways. Our results obtained suggested that TG2 closely associates with integrins b1 and b5 on the surface of drug-resistant MCF-7 cells. The association promoted a strong interaction between drug-resistant cells and Fn-coated surfaces resulting in induction of cell growth and cell survival functions.
Results
We used a human breast carcinoma (MCF-7/WT) cells and the two sublines (MCF-7/Dox, and MCF-7/RT) derived from it for this study. The establishment and other characteristics of these cell lines have been described in earlier publications (Chen et al., , 2004 Devarajan et al., 2002; Mehta et al., 2002) . The relative sensitivity of three cell lines to doxorubicininduced cytotoxicity is shown in Figure 1a . MCF-7/WT cells showed the highest sensitivity to doxorubicin, whereas MCF-7/DOX cells were least sensitive. MCF-7/ RT cells sensitivity to doxorubicin was intermediate. As expected, MCF-7/WT cells completely lacked TG2 and p-glycoprotein (Pgp) expression, whereas MCF-7/Dox and MCF-7/RT cells expressed high levels of TG2. The MCF-7/RT cells lacked Pgp expression, whereas MCF-7/DOX cells showed abundant levels (Figure 1b) .
To determine the role of TG2, if any, in integrinmediated cell survival signaling pathways, we first studied the cell surface expression of TG2 in all the three cell lines. The drug-sensitive MCF-7/WT cells almost completely lacked cell surface expression of TG2, whereas both drug-resistant cell lines (MCF-7/DOX and MCF-7/RT) showed high levels of cell surface TG2 TG2-mediated drug resistance in MCF-7 cells JF Herman et al expression ( Figure 2a ). The cell surface expression of TG2 was slightly higher in MCF-7/RT cells than in MCF-7/DOX cells. Immunofluorescence studies confirmed the flow cytotometry results ( Figure 2b ). As TG2 has been reported to associate with b1 and b3 members of the integrin family of proteins (Akimov et al., 2000; Akimov and Belkin, 2001) , we next examined the cell surface expression of various integrins on drug-sensitive and drug-resistant MCF-7 cells.
Results shown in Figure 3 demonstrated that the surface expression of b1 integrin on TG2-positive drug-resistant MCF-7/RT and MCF-7/Dox cells was three to four-fold higher than in drug-sensitive TG2-negative MCF-7/WT cells. The b3 integrin expression was low in all three cell lines (Figure 3 ) but b5 integrin expression was high in all three (Figure 3 ). Because b1 integrin forms heterodimers with a4 and a5 integrins and b5 uses av as a heterodimer partner, we also determined the expression of these a integrins on MCF-7 cells. Interestingly, the expression of a4 and a5 integrins was extremely low in drug-sensitive MCF-7/WT cells but high in drug-resistant MCF-7/RT and MCF-7/DOX cells ( Figure 3 ). Increased expression of b1, a4, or a5 integrin in MCF-7/RT and MCF-7/DOX cells was not related to TG2 because the forced expression of TG2 by transfection of MCF-7/WT cells failed to alter basal levels of these integrins (data not shown). The av expression was high in all the three cell lines. On the basis of these observations, we hypothesized that differential expression of a4 and a5 integrins and b1 integrin and TG2 expression in drug-resistant cells contribute to the development of drug resistance phenotype. Indeed, a5b1 integrin serves as a natural ligand for Fn (Parise et al., 2000; Danen and Yamada, 2001) , whereas a4b1 integrin heterodimer can bind to both vascular cell adhesion molecule-1 and Fn (Nista et al., 1997) . In view of our observations that drugresistant MCF-7 cells, in addition toTG2, also expressed high levels of a5b1 and a4b1 (ligands for Fn) and the earlier observations that TG2 has a high-binding affinity for Fn (Jeong et al., 1995) , we postulated that TG2 promotes the a4b1 as well as a5b1-mediated interaction of cells to Fn in the ECM and thus induce cell survival signaling pathways. Indeed, interaction of cancer cells with Fn has been shown to promote the cell survival signaling pathways and confer resistance to chemotherapeutic drugs (Zhang et al., 1995; Damiano et al., 1999 Damiano et al., , 2001 Mauro et al., 1999; Aoudjit and Vuori, 2001; de la Fuente et al., 2002; Cordes et al., 2003; Korah et al., 2004) . The 'open' curve shows the fluorescence intensity of integrins as revealed by immunostaining of cells with specific integrin antibody, followed by the flurochrome Alex-488-conjugated secondary antibody as described in Materials and methods. The results shown are from a representative experiment that was repeated at least three times with similar results.
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Therefore, we next examined the possibility that TG2 in drug-resistant MCF-7 cells associates with integrins.
Immunoprecipitates from MCF-7 cell lysates were isolated using anti-b1 integrin antibody and tested for the presence of TG2 protein. Results shown in Figure 4a clearly established that anti-b1 integrin antibody formed complexes with, in addition to b1 protein, TG2 protein from MCF-7/RT and MCF-7/Dox cell lysates. In MCF-7/WT cells the anti-b1 antibody immunoprecipitate failed to show any TG2 band despite the presence of a major band at the b1 integrin position (Figure 4a ). Since b3 integrin expression is low in MCF-7 cells (Figure 3) , coimmunoprecipitation experiments using anti-b3 integrin were not performed. However, b5 integrin, which was abundantly expressed in all the three cell lines, also closely associated with TG2 in drug-resistant MCF-7/DOX and MCF-7/RT cells ( Figure 4b ). Immunprecipitation of irrelevant protein such as, epidermal growth factor receptor (EGF-R), failed to pulldown TG2 (Figure 4c ) suggesting selective interaction between integrin and TG2.
Association of TG2 with b1 and b5 integrins was further supported by confocal microscopy data. As shown in Figure 5a , TG2 (green fluorescence) colocalized with b1 integrin (red fluorescence) in MCF-7/Dox cells as evidenced by the yellow fluorescence in the merged images. Similarly, TG2 also colocalized with b5 integrin in MCF-7/Dox cells ( Figure 5b) . A similar colocalization of TG2 with both b1 and b5 integrins was observed in MCF-7/RT cells (data not shown). However, MCF-7/WT cells, which lacked TG2 expression, did not show any green (TG2) or yellow fluorescence (merged image; data not shown).
Next we determined whether TG2 expression and its interaction with b integrins would confer any cell survival advantage to drug-resistant MCF-7 cells. Culture of TG2-positive MCF-7/DOX and MCF-7/RT cells on Fn-coated surfaces induced significant protection against serum-deprivation-induced cell death (Po0.001; Figure 6a ) as well as stimulation of cell growth (Po0.001 and 0.005 for MCF-7/DOX and MCF-7/RT cells, respectively; Figure 6b ) compared with controls grown on BSA. In MCF-7/WT cells, which lack TG2 expression, cell growth and cell survival on Fn-coated surfaces were comparable to the values in cultures grown on BSA-coated surfaces ( Figure 6 ). These results suggested that breast cancer cells expressing TG2 survive better on Fn-coated surfaces, probably due to the ability of cell surface TG2 to bind to the Fn. Since TG2 is closely associated with b integrins on the surface of these cells, its simultaneous interaction with Fn could activate integrin-mediated cell survival and cell growth signaling pathways and thus confer protection against chemotherapy-induced apoptosis.
To further analyse the involvement of TG2 in Fnmediated cell growth and cell survival signaling, we used a small interfering RNA (siRNA)-based approach. We first tested the ability of siRNAs to downregulate TG2 protein in MCF-7/RT cells. TG2-mediated drug resistance in MCF-7 cells JF Herman et al specific siRNA was consistently 70-90%. The transfection with control siRNA (scrambled) had no appreciable effect on TG2 level (Figure 7a ). However, specific knock-down of TG2 with individual siRNAs (siRNA1 and siRNA2) as shown in Figure 7a and determined by Western blotting, suppressed the protein level by more than 70%. We then analysed the effect of transient knock-down of TG2 on Fn-mediated cell attachment. Results shown in Figure 7b and c demonstrated that inhibition of TG2 by siRNA could effectively block the Fn-mediated attachment and spreading of MCF-7/RT cells. No such effects were observed when the cells were transfected with control nonspecific (scrambled) siRNA. These results suggested that TG2 plays an important role in promoting the attachment and spreading of drugresistant MCF-7 cells to Fn-coated surfaces. In a parallel experiment, untreated and siRNAstransfected MCF-7/RT cells were continued for additional 48 h in serum-free medium on Fn-and BSA-coated plates. After 48 h, the ability of TG2 and Fn to support cell growth and cell survival in presence of serum-free medium was tested by determining the number of viable cells remaining in wells by MTT assay. Results shown in Figure 8a and b confirmed that TG2-positive MCF-7/RT cells when cultured on Fncoated surfaces could survive and grow effectively under serum-free conditions. However, on BSA-coated surfaces these cells completely failed to survive (Figure 8a  and b) . More importantly, knock-down of TG2 in MCF-7/RT cells with siRNAs markedly reduced the survival and growth of these cells even on Fn-coated surfaces (Figure 8a and b) . These results suggest that TG2-dependent interaction between drug-resistant MCF-7 cells and Fn is critical for inducing cell survival and cell growth cues.
As FAK is recruited and activated (autophosphorylated) at a very early stage following the activation of integrins (Zhang et al., 1995) and because TG2 is closely associated with b integrins in MCF-7 cells, we next determined the effect of TG2-Fn interaction on FAK activation. The TG2-expressing MCF-7 (RT and DOX) cells readily adhered to the Fn-coated surfaces after 3 h of incubation, while the TG2-deficient MCF-7/WT showed very little adherence to Fn. All three MCF-7 cell lines showed very little adherence to BSA surfaces. After 3 h of incubation, adherent and non-adherent cells were harvested and cell lysates immunoprecipitated with anti-FAK antibody and the membrane probed with antiphosphotyrosine or anti-FAK antibody as described in Materials and methods. Results shown in Figure 8c revealed a major phosphotyrosine band at the 125-kDa position corresponding to FAK in drug-resistant MCF-7/RT and MCF-7/Dox that had been cultured on Fn. However, no tyrosine phosphorylation of FAK was observed in these cells grown on BSA. Similarly, no tyrosine phosphorylation of FAK was observed in the drug-sensitive TG2-deficient MCF-7/WT cells whether grown on BSA or on Fn-coated plates (Figure 8c ). These results suggested that culture of TG2-positive breast cancer cells promotes adherence to Fn and induces strong activation of FAK, an upstream event that leads to the activation of various downstream antiapoptotic and cell survival signaling pathways (Guan, 1997; Schlaepfer et al., 1999) . To directly test this, we determined the effect of TG2 inhibition on doxorubicin-induced cytotoxicity in MCF-7/RT cells. Results shown in Table 1 suggested that inhibition of TG2 results in partial reversal of drug resistance in MCF-7 cells.
Discussion
Our previous observations suggested that the development of drug-resistance phenotype in human breast cancer MCF-7 cells is associated with increased expression of TG2 (Mehta, 1994; Chen et al., 2002 Chen et al., , 2004 Devarajan et al., 2002; Mehta et al., 2002) . This paper further delineates a role that TG2 might play in conferring the drug-resistance phenotype. Our results demonstrate that TG2 is closely associated with b1 and b5 integrins in drug-resistant breast cancer cells. 
TG2-mediated drug resistance in MCF-7 cells JF Herman et al
Although previous studies by Belkin and his group have demonstrated a similar association of TG2 with b1 and b3 integrins (Akimov et al., 2000; Akimov and Belkin, 2001) , we believe that our study is the first to report an association between TG2 and b5. High expression of TG2 and its association with integrins may represent a novel mechanism of integrin activation and cell-survival signaling pathways in drug-resistant cancer cells. Such association of TG2 with b integrins can promote indirect interaction of integrins with Fn in the extracellular matrix (ECM) due to the high-binding affinity of TG2 for Fn (Jeong et al., 1995) . Therefore, the association of TG2 with b1 and b5 integrins can serve as a bridge for promoting interaction between low-affinity integrins and Fn.
Fn is a major protein in the ECM that plays an important function in inducing cell survival signaling in tumor cells (Longtin, 2004) . For example, culture of a5b1 integrin-expressing cells on Fn is associated with the increased expression of antiapoptotic protein Bcl 2 and with protection from apoptosis (Zhang et al., 1995) . Similarly, several cancer cell lines have been shown to better survive the chemotherapy or radiation-induced cytotoxic effects when cultured on Fn-coated surfaces (Damiano et al., 1999 (Damiano et al., , 2001 Aoudjit and Vuori, 2001; de la Fuente et al., 2002; Cordes et al., 2003; Korah et al., 2004) . Interestingly, the metastatic breast cancer cells MDA-MB-231, which exhibit resistance to chemotherapy (Aoudjit and Vuori, 2001) At 48 h after transfection with control or TG2-specific siRNAs the MCF-7/RT cells were plated (5 Â 10 3 cells/0.2 ml/well) in quadruplicates in 96-well plate. The cells were incubated for 48 h in the presence or absence of increasing doses of doxorubicin in RPMI1640 medium containing 1% FCS. At the end of incubation period cell survival was determined by MTS assay as described in Materials and methods. MCF-7/WT cells were tested in parallel as a control for doxorubicininduced cytotoxicity.
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JF Herman et al high constitutive levels of TG2 protein . Similarly, the interaction between cell surface a5b1 integrin and Fn leads to the activation of signaling pathways that can induce cell growth and contribute to the development of metastatic phenotype (Parise et al., 2000) . The activation of Shc in response to a5b1 and Fn interaction has been shown to modulate the adhesion and motility of breast cancer MCF-7 cells (Mauro et al., 1999) . Similarly, activation of a5b1 integrin as a result of its interaction with Fn or by agonistic antibodies has been shown to induce cyclin D1 expression and activate mitogen-activated protein kinase (MAPK) pathway (Roovers et al., 1999) . Moreover, Fn interaction results in the activation of Cdc42 and Rac-like GTPases that are known to contribute in cell attachment, motility, and invasive functions of cancer cells (Price et al., 1998) . On basis of these observations and the observation that TG2 has a high-binding affinity for Fn (Jeong et al., 1995) , it is tempting to speculate that TG2 in drugresistant cells acts as a bridging molecule to promote interaction between cell surface integrins and the ECM. The TG2-mediated interaction of integrins and Fn can, in turn, induce cell-survival signaling pathways, conferring general resistance to apoptosis. Indeed, several studies have suggested that the apoptosis-resistant phenotype is an important feature of drug-resistant and metastatic tumors.
Moreover, the results presented in this paper further suggested that culture of TG2-positive MCF-7 cells on Fn-coated surfaces results in strong activation of FAK (Figure 7b ). FAK is a nonreceptor protein tyrosine kinase that plays a critical role in signaling events between cells and the ECM. FAK has been linked to integrin-signaling pathways involved in cell migration and apoptosis (Guan, 1997; Schlaepfer et al., 1999) . Thus, cells derived from FAK À/À embryos exhibit reduced migration compared with wild-type cells (Ilic et al., 1995) . Conversely, CHO fibroblasts transfected with FAK showed increased migration on Fn, and mutation in the major autophosphorylation site of FAK abrogated its ability to promote cell migration (Cary et al., 1996) . Moreover, FAK has been shown to serve as a survival signal for anchorage-dependent cells, and its inhibition in tumor cells has been shown to result in cell death (Xu et al., 1998) . Therefore, it is likely that by inducing FAK activation, TG2 helps maintain cell survival during chemotherapy-induced cytotoxicity and metastatic processes. Indeed, FAK expression and activation is frequently associated with the development of metastatic and drug-resistant phenotypes (Sonoda . Cells were incubated in serum-free medium in BSA-or Fn-coated Petri dishes for 2 h at 371C. After the incubation, adherent plus non-adherent cells were lysed and equal amounts of protein were immunoprecipitated with anti-FAK antibody. The immunoprecipitates were fractionated on SDS-PAGE and blotted onto NC membrane. The NC membrane containing the immunoprecipitates was first probed with antiphosphotyrosine antibody, followed by anti-FAK antibody.
TG2-mediated drug resistance in MCF-7 cells JF Herman et al Schlaepfer et al., 2004) . Results reported in this paper clearly demonstrate that inhibition of TG2 attenuates attachment of drug-resistant MCF-7 cells on Fn-coated surfaces. Importantly, TG2 inhibition by siRNA rendered the cells sensitive not only to apoptosis in serum-deprived conditions but also to drug-induced cytotoxicity.
Resistance to apoptosis is an important characteristic of aggressive cancers enabling the cancer cells to withstand not only microenvironmental stresses such as hypoxia, nutritional depletion, and low pH but also to chemotherapy-induced cytotoxic effects. Therefore, further understanding on TG2-mediated cellular interactions with the ECM and signaling pathways induced in response to such interaction may offer new targets for intervention and treatment of drug-resistant and metastatic tumors. In this regard, recent identification of the major Fn-binding site within amino acids 80-140 of TG2 (Hang et al., 2005) may provide useful tools to further understand the significance of TG2-mediated interactions in drug-resistant and metastatic phenotypes.
Materials and methods

Cell lines
Human breast cancer (MCF-7) cells were obtained from American Type Culture Collection (Manassas, VA, USA). The drug-resistant MCF-7/DOX cells were derived from the parental drug-sensitive MCF-7 cells by continuous culture in the presence of doxorubicin (American Pharmaceutical Partners Inc., Los Angeles, CA, USA), as described earlier . To maintain the drug-resistant phenotype, we continuously grew MCF-7/DOX cells in the presence of doxorubicin (1 mg/ml) except 4 days prior to the experiment. The revertant MCF-7 cell line (MCF-7/RT) was established by culturing MCF-7/DOX cells in the absence of doxorubicin for a long time, as described .
Cell viability, growth, and attachment assay In all, 96-well plates (Cornig/Costar, Rochester, NY, USA) were coated with either 20 mg/ml Fn (Sigma-Aldrich, St Louis, MO, USA) in phosphate-buffered saline (PBS) or 0.1% bovine serum albumin (BSA from Sigma) in PBS for 16 h at 41C. The plates were then treated with 0.2% BSA for 1 h at room temperature to block nonspecific binding sites. The cells grown in T-75 flasks to 80-90% confluence were isolated by trypsinization, washed once with RPMI medium, and resuspended at 5 Â 10 4 cells/ml in serum-free RPMI 1640 medium. Aliquots (200 ml) of the cell suspension were added to Fn-or BSA-coated wells in quadruplicate and incubated at 371C for 48 h. At the end of incubation period, the number of viable cells remaining in the well was determined by measuring their ability to reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2H-tetrazolium (MTS) into a soluble formazan, as described .
In some experiments, drug-resistant MCF-7 cells were transfected with TG2-specific (siRNA1 and siRNA2) or control (scrambled) siRNAs using RNAiFect reagent in accordance with the manufacturer's instructions (Qiagen Sciences, Germantown, MD, USA). After the transfction, cells were harvested with 2 mM EDTA, washed twice in RPMI medium and plated (5 Â 10 3 /0.2 ml/well in serum-free medium) in quadruplicate to each well of 96-well plates that had been precoated with Fn or BSA. After 48 h of incubation, cells were examined under the light microscope and tested for cell viability using MTS assay. In some experiments, the cell growth was assayed by 3 [H]-thymidine (Amersham Biosciences Corp., Piscataway, NJ, USA) incorporation. After 48 h of incubation on Fn-or BSA-coated plates, cells were pulse labeled with 3 [H]-thymidine (1 mCi/well) and harvested using a semiautomatic cell harvester (Cambridge Technology Inc., Watertown, MA, USA). Radioactivity was measured using a Tri-Carb liquid scintillation analyser (Packard, Meriden, CT, USA).
For attachment assays the control and siRNAs transfected MCF-7/RT cells (2 Â 10 4 cells/well/0.2 ml serum-free RPMI medium) were incubated in Fn-or BSA-coated 96-well plates. After 1 h incubation at 371C, cells were viewed under microscope for morphology. Non-adherent cells were removed by washing with PBS and adherent cells were fixed with 3.7% parafolmaldehyde for 1 h, washed twice with PBS and stained with 0.1% crystal violet for 40 min. The stained cells were washed with water, lysed in 0.5% Triton X-100, and the optical density was read at 540 nm.
Flow cytometry
To study cell surface profiles of integrins and TG2 expression in MCF-7 cells, anti-a 4 (clone 16983Z), a 5 (clone 1956Z), a v (clone 1953Z), a 6 (clone 1378), b 1 (clone 1965Z), b 3 (clone 1957Z), and b 5 (RB1926) were purchased from Chemicon (Temula, CA, USA). Anti-TG2 (RB050) was purchased from Neomarkers (Fremont, CA, USA) and used at the recommended concentrations. The goat Alexa 488-conjugated antimouse IgG or goat Alexa 488-conjugated anti-rabbit IgG were obtained from Molecular Probes (Eugene, OR, USA) and were used for a 4 , a 5 , a v , a 6 , b 1 , and b 3 detection and b 5 and TG2 detection, respectively. The FACSCalibur flow cytometer from Becton Dickinson (Mountainview, CA, USA) was used to analyse the cells. A total of 10 000 events per sample were analysed.
TG2 enzyme activity
Cell monolayers at 70-80% confluency were washed in PBS, collected, and resuspended in a minimal volume (100-300 ml) of lysis buffer (20 mM Tris-HCl, pH 7.4, containing 1 mM EDTA, 150 mM NaCl, 14 mM 2-mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride). Cells were then lysed in the same buffer by sonication and the protein content determined. Cell lysates were assayed for TG2 activity by determining Ca 2 þ -dependent incorporation of [ 3 H]putrescine (specific activity, 14.3 Ci/mmol; Amersham-Pharmacia, San Francisco, CA, USA) into dimethylcasein . The enzyme activity was expressed as nanomols of putrescine incorporated per hour per milligram of total lysate protein.
Western blot MCF-7 cells grown to 80% confluence in 75 cm 2 flasks were harvested in lysis buffer consisting of 20 mM Tris, 0.15 M NaCl, 0.1% beta-mercaptoethanol, 1 mM EDTA, and protease inhibitors (P-8340, Sigma). The cell lysates were mixed with 3 Â sample buffer and boiled for 5 min. Of the cell lysate proteins, 30 mg were then loaded per lane and fractionated on 8% SDS-PAGE. The primary antibodies used were anti-b1, -b5-integrin, or -TG2. Secondary antibodies were anti-mouse or anti-rabbit IgG horseradish peroxidase. ECL (Amerisham Life Science) was used to detect the antigen-antibody reaction.
Immunoprecipitation Cells were lysed in the extraction buffer containing 20 mM Tris-HCl, pH 7.6; 100 mM NaCl; 0.5% NP-40; and 5 mM EDTA, supplemented with protease inhibitors. Of total cell lysate protein, 500 mg were preclarified by incubation with protein G sepharose beads. The precleared lysates were incubated overnight (41C) with primary antibodies anti-b 1 integrin (kindly provided by Dr Bradley McIntyre of MD Anderson Cancer Center) or anti-b 5 integrin (Chemicon). The next day, antigen-antibody complexes were removed by incubating the solutions with either anti-mouse IgG or antirabbit IgG (1 h at 41C), followed by incubation with G protein sepharose beads (1-3 h at 41C). Beads were washed with the extraction buffer and eluted with 2 Â sample buffer. Bound proteins were analysed by Western blot. To detect TG2 in the immunoprecipitates, membranes were first probed with anti-TG2 (M300) antibody and then with anti-mouse IgG horseradish peroxidase. The membrane was then stripped and reprobed with anti-b 1 or b 5 integrin antibodies.
We also used an immunoprecipitation assay to assess the phosphorylation of focal adhesion kinase (FAK). Cells were incubated in serum-free medium on BSA-or Fn (10 mg/ml)-coated Petri dishes for 3 h at 371C. After the incubation, adherent plus non-adherent cells were lysed, and equal amounts of protein were incubated with anti-FAK antibody (F-2918; Sigma). Immunoprecipitates were recovered as described above and fractionated on 8% SDS-PAGE. The nitrocellulose membrane containing the immunoprecipitates was first probed with antiphosphotyrosine antibody (PY20; Signal Transduction Laboratory), followed by anti-FAK antibody. ECL (Amerisham Life Science) was used to detect antigen-antibody reaction.
Confocal microscopy MCF-7 cells were grown on sterile glass coverslips to 80% confluence. The adherent cells were fixed with 3.7% paraformaldehyde, washed with PBS, and nonspecific binding sites were blocked by incubation with 5% normal goat serum. Cells were then immunostained by using primary antibodies against integrin b 1 or b 5 (Chemicon) and TG2. Either goat anti-mouse IgG Alexa488 or Alexa546 or goat anti-rabbit IgG Alexa488 or Alexa546 (Molecular Probes) were used as the secondary antibodies. Topro 3 (Molecular Probes) in combination with the secondary antibodies was used for staining the nuclei. The stained cells were mounted on glass microscope slides in 80% glycerol plus 20% PBS and viewed under the Zeiss Laser Scanning Microscope for imaging.
